Abstract
Asenapine, a novel psychopharmacologic agent being developed for the treatment of schizophrenia and bipolar disorder, has high affinity for a wide range of receptors, including the serotonergic receptors 5-HT(1A), 5-HT(1B), 5-HT(2A), 5-HT( 2B), 5-HT(2C), 5-HT(5A), 5-HT(6) and 5-HT( 7). We examined the long-term effects in rat brain of multiple doses of asenapine on representative serotonin receptor subtypes: 5-HT(1A), 5-HT(2A) and 5-HT(2C). Rats were given asenapine (0.03, 0.1 or 0.3 mg/kg) subcutaneously twice daily or vehicle for 4 weeks. Brain sections were collected from the medial prefrontal cortex (mPFC), dorsolateral frontal cortex (DFC), caudate putamen, nucleus accumbens, hippocampal CA( 1) and CA(3) regions, and entorhinal cortex and processed for in-vitro receptor autoradiography. Asenapine 0.1 and 0.3 mg/kg significantly increased 5-HT(1A) binding in mPFC (by 24% and 33%, respectively), DFC (27%, 31%) and hippocampal CA(1) region (23%, 25%) (all P < 0.05). All three asenapine doses (0.03, 0.1 and 0.3 mg/kg) significantly decreased 5-HT(2A) binding by a similar degree in mPFC (40%, 44%, 47%, respectively) and DFC (45%, 51%, 52%) (all P < 0.05), but did not alter 5-HT(2A) binding in the other brain regions studied. In...Continue Reading
References
Jan 1, 1990·Synapse·S J O'DellJ F Marshall
Jan 1, 1990·Neuroscience·G MengodJ M Palacios
Dec 1, 1986·Biological Psychiatry·T MitaC Tanaka
Jan 1, 1988·Schizophrenia Bulletin·A BleichH M van Praag
Jan 1, 1987·Annual Review of Biochemistry·A G Gilman
Nov 4, 1985·Brain Research·A Pazos, J M Palacios
Apr 6, 1995·Nature·L H TecottD Julius
Jan 16, 1995·The Journal of Comparative Neurology·D E WrightL Jennes
Jan 1, 1993·Psychopharmacology·T HashimotoC Tanaka
Jan 1, 1993·Psychopharmacology·D C OhuohaJ E Kleinman
Oct 1, 1993·Archives of General Psychiatry·M LaruelleJ E Kleinman
Jun 1, 1993·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·J N JoyceJ E Kleinman
Feb 5, 1996·Brain Research·T SumiyoshiH Y Meltzer
Jul 1, 1996·Neuroscience·P W BurnetP J Harrison
Mar 1, 1996·Psychopharmacology·A SchotteJ E Leysen
Jun 1, 1996·Biological Psychiatry·M D SimpsonJ F Deakin
Oct 6, 1997·Biological Psychiatry·E V Gurevich, J N Joyce
Aug 5, 1999·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·H Y Meltzer
Feb 5, 2000·European Journal of Pharmacology·E P PrinssenM S Kleven
Mar 10, 2001·Journal of Neurochemistry·J IchikawaH Y Meltzer
May 30, 2001·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·F M Benes, S Berretta
Jul 10, 2001·Molecular Psychiatry·M S SodhiP J Harrison
Jan 5, 2002·CNS Drugs·Daniel TarsyFrank I Tarazi
May 22, 2002·Psychopharmacology·Frank I TaraziRoss J Baldessarini
Dec 4, 2003·Progress in Neuro-psychopharmacology & Biological Psychiatry·Herbert Y MeltzerJunji Ichikawa
Apr 13, 2005·Clinical Therapeutics·John W Newcomer
Nov 25, 2005·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Llorenç Díaz-MataixFrancesc Artigas
Feb 24, 2006·NeuroRx : the Journal of the American Society for Experimental NeuroTherapeutics·Shitij KapurMing Li
Aug 15, 2006·Annual Review of Medicine·L Fredrik JarskogJeffrey A Lieberman
Mar 30, 2007·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Miroslav M SavićJames M Cook
Oct 18, 2007·Psychopharmacology·Olivia FrånbergTorgny H Svensson
Oct 27, 2007·The Journal of Clinical Psychiatry·Steven G PotkinJohn Panagides
Citations
May 21, 2009·Journal of Molecular Neuroscience : MN·Yong Kee ChoiFrank I Tarazi
Aug 21, 2013·Neuropharmacology·Rongyin QinMing Li
Nov 16, 2013·CNS Spectrums·Yong Kee ChoiFrank I Tarazi
Aug 6, 2014·Behavioural Brain Research·Qing ShuMing Li
Aug 2, 2012·Expert Opinion on Pharmacotherapy·Frank I Tarazi, Stephen M Stahl
Jul 5, 2011·Expert Review of Neurotherapeutics·Maurizio PompiliPaolo Girardi
Nov 6, 2012·Expert Opinion on Drug Discovery·Frank I Tarazi, Jo C Neill
Feb 18, 2016·Neurological Research·Z Majercikova, A Kiss
Sep 12, 2015·Acta Neuropsychiatrica·Hila M EneHaim Einat
Aug 31, 2014·Brain Research Bulletin·Zuzana MajercikovaAlexander Kiss
Jan 30, 2013·Expert Opinion on Pharmacotherapy·Andrea FagioliniFrancesco Casamassima
Feb 5, 2015·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Andrea de BartolomeisCarmine Tomasetti
Oct 10, 2013·Behavioural Brain Research·Jun Gao, Ming Li
Oct 20, 2009·The International Journal of Neuropsychopharmacology·Yong Kee ChoiFrank I Tarazi
Jul 1, 2016·CNS Drugs·Greg L Plosker, Emma D Deeks
Jun 28, 2016·Expert Opinion on Drug Safety·L OrsoliniD De Berardis
Oct 28, 2016·Brain Research Bulletin·Zuzana MajercikovaAlexander Kiss
Oct 21, 2016·Neuropeptides·Alexander Kiss, Zuzana Majercikova
Jan 7, 2017·CNS Spectrums·Yong Kee ChoiFrank I Tarazi
Jun 10, 2017·Synapse·Yong Kee ChoiFrank I Tarazi
Aug 12, 2010·Journal of Psychopharmacology·Hugh M MarstonMohammed Shahid
May 4, 2018·Expert Opinion on Drug Discovery·Anna WesołowskaMarcin Kołaczkowski
Dec 1, 2011·Therapeutic Advances in Psychopharmacology·Gavin P Reynolds
Jul 2, 2011·Journal of Clinical Psychopharmacology·Mohammad Jafferany, Melissa A Silverman
Feb 18, 2011·CNS Drugs·Claudine M Chwieduk, Lesley J Scott
Aug 10, 2018·Journal of Molecular Neuroscience : MN·Yong Kee Choi, Frank I Tarazi
Mar 23, 2011·Current Opinion in Pharmacology·H Y Meltzer, B W Massey